That same month, the journal Science declared glucagon-like peptide-1 (GLP-1) weight loss drugs its Breakthrough of the Year, beating out commendable contenders such as new malaria and Alzheimers treatments, innovative climate change research on natural carbon pumps and artificial intelligence (AI) in improving weather forecasting
The answer requires separating three distinct peptide categories: GLP-1 receptor agonist peptides: semaglutide, liraglutide, tirzepatide (dual GIP/GLP-1)
This area is accessible and relatively easy to inject, making it a good choice for healthcare professionals
But BPC-157 brings it back up
Schindler believes stopping people from becoming obese to begin with, rather than treating them after the fact, might in fact require an industrywide effort
2016 [cited 2021 Dec 27];24:227888